Please ensure Javascript is enabled for purposes of website accessibility

Will Mixing Different COVID Vaccines Be Likely Down the Road?

By Keith Speights and Brian Orelli, PhD - Updated Jun 25, 2021 at 3:07PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Maybe, but maybe not.

If you receive the first dose of one company's COVID-19 vaccine, you get a second dose of that same vaccine. However, "mix-and-match" clinical studies are under way that are evaluating how well a second dose of a different vaccine might work. And some early results for this approach appear to be promising. In this Motley Fool Live video recorded on May 26, Motley Fool contributors Keith Speights and Brian Orelli discuss whether or not mixing COVID-19 vaccines will be likely down the road.

Keith Speights: I did see something interesting, Brian, something just came to the top of my mind. I saw some results from a study conducted in Spain where a combination of the first dose of AstraZeneca's (AZN 1.01%) vaccine with the second dose of Pfizer's (PFE 1.17%) vaccine actually seem to be much more effective, at least created much higher neutralizing antibody levels than the AstraZeneca vaccine by itself, or two doses of Pfizer's vaccine.

It hasn't been peer-reviewed yet. Relatively small study. Who knows if it'll be confirmed. But that's at least interesting to me that some of these mix-and-match possibilities could create some interesting market dynamics here.

Brian Orelli: Yeah, and that makes sense because they're all developing it to the spike protein, which is the outside part that attaches to the cell to inject its RNA into the cell that ends up making more virus. The proteins aren't necessarily exactly the same. They are part of the spike protein but they may not follow exactly the same.

It would make sense that getting more than one vaccine might be beneficial in creating different kinds of antibodies. Then when you're measuring neutralizing antibodies you're basically just throwing all the antibodies in with the virus. That would allow them to bind to different parts of the virus and theoretically have a higher blocking level than in individual.

Speights: There's some other mix-and-match clinical studies going on that I'm sure we'll be talking about some in the future because it could be interesting to see how efficacy varies when you mix and match different vaccines together. I'm not sure that that will necessarily impact the market in a huge way going forward because my hunch is that maybe after some time into next year, that we'll probably transition to single-shot booster doses instead of multiple doses. If that happens as I suspect will happen then these mix-and-match studies might not matter all that much.

Orelli: I think we're probably going to get pretty close to where we are with the flu vaccines, where you go in and get a flu vaccine, but you don't know what brand you got. That's probably true of most vaccines. I think that COVID-19 is probably one of the few exceptions where people actually know what brand of vaccine they got.

Brian Orelli, PhD has no position in any of the stocks mentioned. Keith Speights owns shares of Pfizer. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$49.15 (1.17%) $0.57
AstraZeneca PLC Stock Quote
AstraZeneca PLC
AZN
$67.17 (1.01%) $0.67

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
397%
 
S&P 500 Returns
128%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/20/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.